Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells

Blood

Volumn 111, Issue 3, 2008, Pages 1387-1395

  Guihot, Amélie ^a   Oksenhendler, Eric ^b   Galicier, Lionel ^b   Marcelin, Anne Geneviève ^a   Papagno, Laura ^a   Bedin, Anne Sophie ^a   Agbalika, Félix ^b   Dupin, Nicolas ^c   Cadranel, Jacques ^d   Autran, Brigitte ^a   Carcelain, Guislaine ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c université Paris Cité   (France)

^d HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HLA B7 ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; VIRUS CARRIER; VIRUS LOAD;

EID: 38949103398     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-03-080648     Document Type: Article

References (40)

1. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. Aids. 1996;10:61-67.
2. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86:1276-1280.
3. Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis. 1997;175:1198-1201.
4. Guihot A, Couderc LJ, Agbalika F, et al. Pulmonary manifestations of multicentric Castleman's disease in HIV infection: a clinical, biological and radiological study. Eur Respir J. 2005;26:118-125.
5. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol. 2000;156:743-749.
6. van Lier RA, ten Berge IJ, Gamadia LE. Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol. 2003;3:931-939.
7. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
8. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
9. van Baarle D, Kostense S, van Oers MH, et al. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol. 2002;23:586-591.
10. Dunne PJ, Faint JM, Gudgeon NH, et al. Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood. 2002;100:933-940.
11. Sacre K, Carcelain G, Cassoux N, et al. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med. 2005;201:1999-2010.
12. van Baarle D, Kostense S, Hovenkamp E, et al. Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection. Aids. 2002;16:2001-2011.
13. Harari A, Vallelian F, Meylan PR, et al. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005;174:1037-1045.
14. Betts MR, Nason MC, West SM, et al. HIV non-progressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood. 2006;107:4781-4789.
15. Osman M, Kubo T, Gill J, et al. Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol. 1999;73:6136-6140.
16. Wang QJ, Jenkins FJ, Jacobson LP, et al. CD8+ cytotoxic T lymphocyte responses to lytic proteins of human herpesvirus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals. J Infect Dis. 2000;182:928-32.
17. Wang QJ, Huang XL, Rappocciolo G, et al. Identification of an HLAA*0201-restricted CD8(+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood. 2002;99:3360-3366.
18. Micheletti F, Monini P, Fortini C, et al. Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. Immunology. 2002;106:395-403.
19. Ribechini E, Fortini C, Marastoni M, et al. Identification of CD8+ T cell epitopes within lytic antigens of human herpesvirus 8. J Immunol. 2006;176:923-930.
20. Wang QJ, Jenkins FJ, Jacobson LP, et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood. 2001;97:2366-2373.
21. Woodberry T, Suscovich TJ, Henry LM, et al. Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins. J Infect Dis. 2005;192:622-629.
22. Brander C, O'Connor P, Suscovich T, et al. Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis. 2001;184:119-126.
23. Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol. 2002;76:2634-2640.
24. Stebbing J, Bourboulia D, Johnson M, et al. Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol. 2003;77:4306-4314.
25. Guihot A, Dupin N, Marcelin AG, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis. 2006;194:1078-1088.
26. Bourboulia D, Aldam D, Lagos D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. Aids. 2004;18:485-493.
27. Lambert M, Gannage M, Karras A, et al. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood. 2006;108:3871-3880.
28. Alatrakchi N, Di Martino V, Thibault V, et al. Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors coinfected with hepatitis C virus. Aids. 2002;16:713-717.
29. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. 1996;348:1133-1138.
30. Lallemand F, Desire N, Rozenbaum W, et al. Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay. J Clin Microbiol. 2000;38:1404-1408.
31. Sharp TV, Wang HW, Koumi A, et al. K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J Virol. 2002;76:802-816.
32. Staskus KA, Sun R, Miller G, et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol. 1999;73:4181-4187.
33. Choi JK, Lee BS, Shim SN, et al. Identification of the novel K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome. J Virol. 2000;74:436-446.
34. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
35. Legoff J, Amiel C, Calisonni O, et al. Early impairment of CD8+ T cells immune response against Epstein-Barr virus (EBV) antigens associated with high level of circulating mononuclear EBV DNA load in HIV infection. J Clin Immunol. 2004;24:125-134.
36. Samri A, Durier C, Urrutia A, et al. Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay. Clin Vaccine Immunol. 2006;13:684-697.
37. Ait-Arkoub Z, Robert-Visse C, Calvez V, et al. No influence of human herpesvirus 8 infection on the progression of HIV-1 infection in initially asymptomatic patients. Aids. 2003;17:1394-1396.
38. + T cells specific for HIV-1 GAG but not for NEF define immune correlates of protection in LTNP. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI), February 8, 2006. Denver, CO. Abstract 442.
39. Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med. 2003;198:1369-1380.
40. Ochsenbein AF, Riddell SR, Brown M, et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med. 2004;200:1407-1417.